Unsurprisingly, sensitivity to α-LGR5 ADC treatment increased proportionally to LGR5-expression indicating the potential for an accessible therapeutic window that can be exploited to eliminate LGR5+ tumour cells while avoiding on-target/off-tumour toxicity to healthy cells [22]. Here, LGR5 is linked to neoplasm.